Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Abstract Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A rec...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0622-4 |